• Users Online: 360
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2014  |  Volume : 5  |  Issue : 2  |  Page : 117-121

Role of the ACTH test and estimation of a safe dose for high potency steroids in vitiligo: A prospective randomized study


1 Department of Dermatology, Dr. José E. González University Hospital, Monterrey, Nuevo León, Mexico
2 Department of Endocrinology, Dr. José E. González University Hospital, Monterrey, Nuevo León, Mexico

Correspondence Address:
Alberto de la Fuente-García
Department of Dermatology, Dr. José E. González University Hospital, Av. Francisco I. Madero Pte y Av. Gonzalitos s/n. Colonia Mitras Centro, C.P. 64460, Monterrey, Nuevo León
Mexico
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2229-5178.131071

Rights and Permissions

Background: Topical corticosteroids are used as first line of therapy for vitiligo, although side effects such as adrenal insufficiency are possible. Objectives: To establish the role of ACTH test before, during, and after treatment with high potency topical steroids; to determine if adrenal insufficiency occurs secondary to the use of high potency topical steroids in patients with vitiligo and intact cutaneous barrier; and also to determine response to treatment and side effects. Materials and Methods: Forty-four adults with non-segmental vitiligo affecting 20% or less of the body surface area were included and randomized to receive topical clobetasol propionate 0.05% cream (group 1) or placebo (group 2) for 12 weeks, with a maximum dose of 50 g per week. The placebo group was crossed over after week 6 and started on clobetasol until completion of the study. Serum cortisol levels with the 1 μg ACTH test were determined at baseline and on weeks 6 and 12. Results: No adrenal insufficiency was detected nor statistical significance was achieved when comparing cortisol levels between and within the groups at baseline and weeks 6 and 12. Group 1 had a better response to therapy but with more side effects. Conclusions: Doses of 50 g or less per week of clobetasol during a period of 12 weeks are safe on adult vitiligo patients, although local side effects are possible. Repigmentation rates were incomplete with single steroid therapy, making combined therapy a better option.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2457    
    Printed31    
    Emailed1    
    PDF Downloaded417    
    Comments [Add]    
    Cited by others 1    

Recommend this journal